Peptide mapping is the principal technique to confirm a protein primary structure (amino acid) and a key step in the biopharmaceutical’s characterization.
At AMSbiopharma, we have developed a liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) based peptide mapping platform for confirmation of primary structure of your biopharmaceuticals in compliance with ICH Q6B guidelines.
Our peptide mapping technology can help our clients to comply with ICH Q6B guidelines, which can also give support to:
• Post-translational modification (PTMs): Including glycosylation, oxidation, deamidation and N-C terminal sequence modifications.
• Disulfide bridges: Free thiols and disulfide bonds cause differences in peptide map allowing to determine the position of disulfide cross-links.
• Purity/impuritie: Peptide mapping can help to characterize process-related protein impurities.
Cookie | Description | ||
---|---|---|---|
Cookie | Description |
---|---|
Cookie1 | Cookie1 Prueba |
cookielawinfo-checkbox-necessary | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-non-necessary | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Non Necessary". |
test_cookie | Test Description |
viewed_cookie_policy | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |